--- title: CDMO Daily News — August 6, 2026 slug: daily-news-2026-08-06-cdmo site: cdmo post_kind: news byline: BioBM description: August 6 CDMO daily: AsymBio Secures $184M to Expand Biologics Manufacturing and GMP Capacity; CordenPharma Completes AmbioPharm Acquisition, Adds U.S. and… canonical_url: https://www.cdmo.directory/posts/daily-news-2026-08-06-cdmo published_at: 2026-08-06T00:00:32.472Z last_updated: 2026-08-06T00:01:48.785Z --- ### [AsymBio](/companies/asymbio) Secures $184M to Expand Biologics Manufacturing and GMP Capacity - [AsymBio](/companies/asymbio) raised 1.2397 billion yuan ($184M) from [Asymchem](/companies/asymchem) Group, Hillhouse Qirui, and others to fund manufacturing expansion, GMP lines, and high-containment facilities. - [Asymchem](/companies/asymchem) Group's stake in AsymBio will increase to 83.5% post-closing, reinforcing the parent's end-to-end CDMO and contract manufacturing strategy. - AsymBio reported 2025 revenue of 470M yuan and Q1 2026 revenue exceeding 140M yuan, with capabilities spanning early-stage development through commercial manufacturing and ADC production. **Operational Impact** [AsymBio](/companies/asymbio)'s $184M capacity expansion and new GMP lines increase available biologics manufacturing slots in the [Asymchem](/companies/asymchem) ecosystem, particularly for ADC and protein therapeutics programs seeking clinical-to-commercial scale-up. *Source: [PharmaSource RSS](https://pharmasource.global/content/news/cdmo-news/asymbio-secures-1-2397-billionapproximately-184-million-yuan-to-expand-biologics-cdmo-capacity)* --- ### [CordenPharma](/companies/cordenpharma) Completes [AmbioPharm](/companies/ambiopharm) Acquisition, Adds U.S. and Asia Peptide Capacity - [CordenPharma](/companies/cordenpharma) acquired peptide CDMO [AmbioPharm](/companies/ambiopharm), integrating facilities in North Augusta, South Carolina and Shanghai, China into its manufacturing network. - South Carolina site expands downstream capabilities (purification, lyophilization); Shanghai adds upstream peptide manufacturing capacity. - Combined network reaches ~3,500 employees and now spans North America, Europe, and Asia with peptide APIs, sterile injectables, and oral solid dosage capabilities. **Operational Impact** [CordenPharma](/companies/cordenpharma)'s integration of [AmbioPharm](/companies/ambiopharm)'s South Carolina and Shanghai facilities adds dedicated peptide upstream and downstream capacity across two continents, reducing single-geography risk for peptide programs in development and commercial phases. *Source: [PharmaSource RSS](https://pharmasource.global/content/news/cdmo-news/cordenpharma-completes-acquisition-of-ambiopharm-to-expand-peptide-cdmo-network)* --- ### [Altasciences](/companies/altasciences) Expands Harleysville R&D Lab with Integrated Formulation and Analytical Testing - [Altasciences](/companies/altasciences) added 768 sq ft of R&D laboratory space at its Harleysville, Pennsylvania drug-product formulation and manufacturing facility. - The integrated lab combines formulation development and analytical testing to accelerate early-stage drug development for small molecules, peptides, and complex modalities. - The expansion includes scientific team growth and supports non-GLP and GLP toxicology sample preparation for nonclinical studies. **Operational Impact** [Altasciences](/companies/altasciences)' Harleysville expansion strengthens early-stage CDMO capabilities and reduces formulation-to-clinic timelines by co-locating development and testing, allowing clients to optimize products before regulated studies. *Source: [PharmaSource RSS](https://pharmasource.global/content/news/cdmo-news/altasciences-expands-rd-laboratory-to-integrate-formulation-and-analytical-testing)* --- ### [Piramal Pharma Solutions](/companies/piramalpharmasolutions) Opens Spray-Drying Suite for Peptide Formulation in India - [Piramal Pharma Solutions](/companies/piramalpharmasolutions) commissioned a spray-drying suite at its Turbhe, India facility to support peptide and complex-molecule formulation development and manufacturing. - The closed-loop system handles potent compounds up to Band 5 containment, maintains ISO Class 8 cleanliness, and processes feed rates up to 1 L/h for high-potency, small-volume batches. - The investment addresses peptide formulation challenges including stability, bioavailability, and scale-up, expanding Piramal's CDMO capabilities across multiple therapeutic areas. **Operational Impact** Piramal's new spray-drying suite at Turbhe expands its peptide CDMO capacity in India, enabling formulation support for high-potency batches and potentially attracting sponsors seeking potent-compound handling expertise in APAC. *Source: [PharmaSource RSS](https://pharmasource.global/content/news/cdmo-news/piramal-pharma-solutions-launches-spray-drying-suite-for-peptide-development)* --- ### Taysha Secures Commercial Manufacturing with [Catalent](/companies/catalent) for Gene Therapy TSHA-102 - Taysha Gene Therapies expanded its partnership with [Catalent](/companies/catalent) to a commercial supply agreement for TSHA-102, an investigational AAV gene therapy for Rett syndrome. - Catalent will serve as primary commercial manufacturer from its FDA-licensed gene therapy facility in Harmans, Maryland, following potential FDA approval. - BLA-enabling Process Performance Qualification activities are underway; the agreement provides long-term capacity and scalable supply framework for commercial launch. **Operational Impact** [Catalent](/companies/catalent)'s Harmans gene-therapy facility gains a commercial-stage AAV program, adding to its 90+ gene therapy programs and demonstrating continued capacity utilization in rare-disease manufacturing. *Source: [PharmaSource RSS](https://pharmasource.global/content/news/cdmo-news/taysha-signs-commercial-supply-agreement-with-catalent-for-tsha-102)* ## References 1. [PharmaSource RSS — AsymBio Secures $184M to Expand Biologics Manufacturing and GMP Capacity](https://pharmasource.global/content/news/cdmo-news/asymbio-secures-1-2397-billionapproximately-184-million-yuan-to-expand-biologics-cdmo-capacity) 2. [PharmaSource RSS — CordenPharma Completes AmbioPharm Acquisition, Adds U.S. and Asia Peptide Capacity](https://pharmasource.global/content/news/cdmo-news/cordenpharma-completes-acquisition-of-ambiopharm-to-expand-peptide-cdmo-network) 3. [PharmaSource RSS — Altasciences Expands Harleysville R&D Lab with Integrated Formulation and Analytical Testing](https://pharmasource.global/content/news/cdmo-news/altasciences-expands-rd-laboratory-to-integrate-formulation-and-analytical-testing) 4. [PharmaSource RSS — Piramal Pharma Solutions Opens Spray-Drying Suite for Peptide Formulation in India](https://pharmasource.global/content/news/cdmo-news/piramal-pharma-solutions-launches-spray-drying-suite-for-peptide-development) 5. [PharmaSource RSS — Taysha Secures Commercial Manufacturing with Catalent for Gene Therapy TSHA-102](https://pharmasource.global/content/news/cdmo-news/taysha-signs-commercial-supply-agreement-with-catalent-for-tsha-102) Source: https://www.cdmo.directory/posts/daily-news-2026-08-06-cdmo